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	Introduction		Adrenocortical	carcinoma	(ACC)	is	a	rare	and	aggressive	endocrine	tumor	that	is	actively	secreting	in	approximately	50%	of	adult	patients.	Cushing’s	syndrome	is	the	most	commonly	associated	endocrine	disorder	 [1]	 that	 negatively	 influences	 the	 outcome	 of	 ACC	 patients,	 due	 to	 cortisol-related	comorbidities	 [2]	 and	 the	 immunosuppressive	 effects	 of	 cortisol	 excess	 that	 may	 promote	 tumor	progression	 [3].	The	management	of	ACC	patients	 is	 challenging	and	demanding	because	physicians	have	to	deal	with	either	oncological	or	endocrinological	issues	[4].		Currently,	 the	standard	systemic	treatment	for	advanced	ACC	patients	not	amenable	to	surgery	with	radical	 intent	 is	mitotane,	 administered	 either	 alone	 or	 in	 combination	with	 etoposide,	 doxorubicin	and	cisplatin	(EDP-M	scheme)	[1].	Mitotane	exerts	both	adrenolytic	and	cytotoxic	activities	[5]	and	has	a	narrow	therapeutic	 index	defined	by	circulating	 levels	of	 the	drug	between	14	mg/L	and	20	mg/L	[6].	 These	 concentrations	 have	 been	 associated	 with	 drug	 activity	 and	 are	 usually	 obtained	 after	several	weeks	to	months	of	treatment	[7].	A	slow	onset	of	mitotane	activity	is	a	main	limitation	also	for	the	management	 of	 Cushing's	 syndrome,	 which	 needs	 to	 be	 treated	 promptly	 not	 only	 to	 ensure	 a	rapid	 correction	of	 the	metabolic	 complications	 that	may	be	 life-threatening	when	cortisol	 excess	 is	severe,	but	also	to	improve	patient	well	being	aiming	to	make	feasible	antineoplastic	therapies.	Thus,	there	is	a	need	to	associate	drugs	able	to	reduce	serum	cortisol	levels	in	an	effective	and	fast	way.		Metyrapone	(Cormeto,	HRA	Paris)	is	an	adrenolytic	molecule	targeting	the	11-beta-hydroxylase	that	is	currently	used	to	treat	Cushing's	syndrome	of	different	etiologies	[8].	The	drug	inhibits	the	conversion	of	11-deoxycortisol	into	cortisol	obtaining	the	reduction	of	cortisol	synthesis	within	2	hours	after	the	first	drug	administration	[9].		Metyrapone	metabolism	and	elimination	are	not	altered	by	concomitant	mitotane,	which	is	known	to	be	 a	 strong	 hepatic	 enzyme	 inducer	 [10].	 Indeed,	 metyrapone	 is	 mainly	 metabolized	 by	 hepatic	reduction;	 mety
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glucuronides	 and	 nearly	 40%	of	 the	 administered	 dose	 is	 excreted	 in	 the	 urine	within	 2	 days	 [11].	There	is	limited	evidence	from	isolated	case	reports	or	small	case	series	that	metyrapone	is	effective	in	the	management	of	hypercortisolism	induced	by	ACC,	but	the	drug	administered	alone	did	not	show	to	have	an	effective	antineoplastic	action	[8;12].	We	reported	herein	the	feasibility	and	activity	of	the	combination	of	metyrapone	with	EDP-M	in	three	consecutive	advanced	ACC	patients	with	Cushing's	syndrome.			Patients	and	methods	From	 January	 to	 June	 2016,	 3	 consecutive	male	 patients	with	 newly	 diagnosed	 ACC	 and	 full-blown	Cushing's	syndrome	were	referred	to	the	Medical	Oncology	Unit	of	ASST	Spedali	Civili	of	Brescia,	Italy.	Two	patients	had	metastatic	disease	(lung	and	supra-clavicular	lymphnode	involvement,	respectively),	one	 had	 inoperable	 locally	 advanced	 disease.	 All	 patients	 presented	 with	 poor	 general	 conditions,	elevated	levels	of	serum	and	urinary	cortisol	and	severe	hypokalemia	(Table	1).	A	complete	hormonal	evaluation	was	performed	at	baseline	and	immediately	after	the	patients	received	EDP-M	(etoposide	100	mg/m²	iv.	on	days	2,	3	and	4,	doxorubicin	40	mg/m²	iv.	on	day	1,	cisplatin	40	mg/m²	iv.	on	days	3	and	4,	plus	mitotane	at	 an	 initial	dose	of	1	g	daily,	with	progressive	 increase	up	 to	6	g	daily,	 or	 the	maximum	 tolerated	dose).	The	 chemotherapy	 regimen	was	given	 in	association	with	metyrapone	at	the	 initial	 daily	 dose	 of	 250	 mg/tid	 per	 os	 [8;9]	 and,	 at	 each	 cycle,	 patients	 received	 pegylated	granulocyte	 colony	 stimulating	 factor	 (G-CSF)	 for	 chemotherapy-induced	 neutropenia	 primary	prophylaxis.			
 
Results 
During	 the	 first	4	weeks	of	 treatment,	 the	patients’	 conditions	markedly	 improved	and	urinary	 free	cortisol	(UFC)	dropped	significantly,	while	the	reduction	of	serum	cortisol	was	less	evident	(Table	1).	The	 metyrapone	 dose	 was	 gradually	 tapered	 over	 time	 according	 to	 clinical	 improvement	 of	 the	Cushing’s	syndrome.	The	drug	was	then	discontinued	after	16	weeks	in	patient	1,	12	weeks	in	patient	
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2	and	8	weeks	 in	patient	3.	None	of	 the	patients	received	steroid	replacement	over	 the	12	weeks	of	therapy	 considered	 in	 this	 case	 series.	 Disease	 restaging	 performed	 at	 week	 12	 showed	 a	 partial	response	and	a	minor	response	(<	30%	reduction	not	qualifying	for	a	partial	response	according	to	the	RECIST	criteria)	 in	patient	3	and	2,	respectively	(Table	1).	Both	patients	underwent	surgery	and	are	currently	disease	 free	 at	 9	 and	7	months	of	 follow-up	 (patient	 3	 and	2,	 respectively).	 The	patient	 1	developed	disease	progression	after	three	months	and	was	subsequently	referred	to	a	palliative-care	program,	due	to	the	deterioration	of	his	general	conditions.		During	the	EDP-M-metyrapone	combination	regimen,	the	major	toxicities	observed	were	asthenia	and	nausea.	Two	patients	 (patient	1	and	2)	 received	red	blood	cell	 transfusion	 for	 severe	grade	anemia.	None	 of	 the	 patients	 developed	 neutropenia,	 due	 to	 the	 adoption	 of	 primary	 prophylaxis.	 Patient	 1	transiently	 interrupted	 both	metyrapone	 and	mitotane	 for	 6	 days,	 due	 to	 the	 persistence	 of	 severe	nausea	and	asthenia	after	chemotherapy	administration.			Discussion	Metyrapone	is	an	effective	drug	to	manage	Cushing’s	syndrome	of	either	origin	[8].	The	drug	has	been	also	employed	in	the	management	Cushing's	syndrome	associated	with	ACC	either	administered	alone	or	in	association	with	other	inhibitors	of	steroidogenesis	[8],	or	chemotherapy	[13;14].	At	the	best	of	our	knowledge,	there	are	no	published	data	on	feasibility	and	activity	of	this	drug	in	association	with	the	current	standard	therapy	for	advanced	ACC,	EDP	plus	mitotane.	Due	to	its	pharmacokinetic	characteristics,	metyrapone	displays	a	good	safety	profile	with	minor	drug-to-drug	interactions	[15].		No	interactions	have	been	reported	with	mitotane	and/or	EDP	[11].	In	the	present	case	series,	the	addition	of	metyrapone	to	EDP-M	led	to	a	rapid	resolution	of	symptoms	and	signs	of	Cushing's	syndrome	and	a	significant	improvement	of	the	patient	general	conditions.	The	control	of	cortisol	hypersecretion	was	obtained	in	few	days	in	patient	2;	the	rapid	increase	of	mitotane	serum	levels	in	this	patient	may	have	likely	contributed	to	the	effect.	We	would	like	to	underline	this	finding,	 because	 EDP-M	 requires	 several	weeks	 to	 attain	 a	 control	 of	 hypercortisolism.	Metyrapone	was	well	 tolerated	and	did	not	 increase	the	toxicity	of	the	EDP-M	regimen,	since	we	did	not	observe	unexpected	toxicities	[16;17].	The	three	patients	included	in	this	report	completed	the	chemotherapy	
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plan	 and	 adding	metyrapone	 to	 the	EDP-M	 regimen	did	 not	 alter	 EDP-M	efficacy	 in	 terms	of	 tumor	control,	since	2	patients	obtained	a	disease	response	and	underwent	radical	surgery.			In	conclusion,	this	case	series	shows	that	the	combination	of	EDP-M	with	metyrapone	is	effective	and	leads	 to	 a	 rapid	 control	 of	Cushing's	 syndrome	 induced	by	 cortisol-secreting	ACC.	This	 combination	may	represent	a	rapid,	effective	and	well-tolerated	treatment	of	excess	hormone	secretion	in	advanced	ACC.	Our	results,	although	interesting,	need	validation	in	a	prospective	study.		Disclosures	Conflict	of	Interest:	The	authors	declare	that	they	have	no	conflict	of	interest.	Funding:	This	study	was	funded	by	Associazione	Italiana	per	la	Ricerca	sul	Cancro	(AIRC),	grant	n.	IG	2015-17678	 to	MT	and	by	a	private	grant	 from	the	amateur	dramatics	group	“Attori	non	per	caso”,	parish	church	of	Collio	Valtrompia	(Brescia)	to	BL.	
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Table 1 - Clinical features, laboratoy assays and hormonal evaluations of three patients with severe Cushing’s Syndrome induced by advanced 
ACC at baseline and after 4, 8 and 12 weeks of treatment with metyrapone, EDP and mitotane.	
 	 Patient 1  	  	 Patient 2 	  	 Patient 3 	
 	 Reference range 	
Baselin
e 	 Week 4 	 Week 8 	
Week 
12 	 Baseline 	
Week 
4 	
Week 
8 	
Week 
12 	
Baselin
e 	
Week 
4 	 Week 8 	 Week 12 	
Age (years) 	  	 66	  	  	  	 53	  	  	  	 40	  	  	  	
Disease 
stage 	  	 IV	  	  	  	 IV	  	  	  	 III	  	  	  	
PS ECOG 	  	 1	 1	 2	 2	 3	 3	 2	 2	 2	 1	 1	 1	
Secretory 
status 	 	 Cortisol		 	 	 	 Cortisol	 	 	 	 Cortisol		 	 	 	
Mitotane 
daily dose 
(mg) 	
 	 3000	 discontinued	 3000	 3000	 3000	 3000	 3000	 3000	 3000	 3000	 3000	 3000	
Metyrapone 
daily dose 
(mg) 	
 	 750	 discontinued	 500	 250	 750	 500	 250	 250	 750	 750	 discontinued	 discontinued	
Mitotane 
serum level 
(µg/dL) 	
14	–	20		  	  	  	 6	  	  	  	 13	  	  	  	 1	
Serum 
cortisol 
5	-	20	(morning	 36	 24	 21	 17	 29	 19	 8	 6	 32	 11	 15	 14	
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
(µg/dL) 	 values)		
UFC 
(µg/24h) 	 10	-	116	 334	 114	 n.a.	 87	 136	 13	 13	 n.a.	 >	600	 26	 n.a.	 61	
ACTH 
(pg/mL) 	 <	46		 <5	 12	 9	 <	5	 <5	 <5	 <5	 <5		 <	5	 21	 55	 94	
DHEAS 
(ng/mL) 	 0,80-5,6		 13	 12	 4	 n.a.		 0	 0	 <	0,15	 <0,15	 7	 1	 0	 0	
Weight Kg 
(BMI) 	  	 			70						(26,53)	 			57				(21,45)	 				60						(22,58)	 57,5			(21,64)	 			116			(39,21)	 		105		(35,49)	 			105		(35,49)	 				107						(36,17)	 				78,5						(25,63)	 					78,5						(25,63)	 						78							(25,47)	 						74,5								(24,33)	
Central 
obesity 	  	 yes	 no	 no	 no	 yes	 yes	 yes	 yes	 yes	 yes	 no	 no	
Glucose 
(mg/dL) 	 70-100		 77	 72	 75	 110	 124	 89	 79	 90	 148	 87	 91	 92	
K+ (mEq/L) 	 3,3-4,7		 3	 5	 4	 4	 3	 4	 4	 4	 3	 4	 4	 4	
EDP major toxicities 	  	  	  	  	  	  	  	  	  	  	  	  	
 	
Nausea/
Vomitin
g 	
 	 G3	 G3	 G2	  	 G0	 G0	 G0	  	 G2	 G1	 G1	
Astheni
a 	  	 G3	 G3	 G3	  	 G2	 G2	 G1	  	 G2	 G1	 G1	
Neutrop
enia 	  	 Primary	prophylaxis	  	 Primary	prophylaxis	  	 Primary	prophylaxis	
Anemia 	  	 G3	 G1	 G1	  	 G3	 G1	 G1	  	 G2	 G1	 G1	
Thromb
ocytope
nia 	
 	 G2	 G1	 G1	  	 G0	 G0	 G0	  	 G0	 G0	 G0	
Disease 
response 	  	  	  	  	 PD	  	  	  	 MR	  	  	  	 PR	Disease	stage	according	to	ENSAT	(European	Network	for	the	Study	of	Adrenal	Tumors);	PS	ECOG:	Eastern	Cooperative	Oncology	Group	Performance	Status;	UFC:	urinary	free	cortisol;	ACTH:	adrenocorticotropic	hormone;	DHEAS:	dehydroepiandrosterone;	BMI:	Body	Mass	Index;	K+:	serum	potassium	levels;	yes:	precence	of	the	charateristic;	no:	 absence	of	 the	 charateristic;	EDP:	 etoposide,	doxorubicin	and	 cisplatin	 (chemotherapy	 scheme);	n.a.:	 not	 available;	Toxicities	 according	 to	CTCAE:	Common	Toxicity	Criteria	 for	Adverse	Event	ver.	4.03	(2010):	G1	mild,	G2	moderate,	G3	severe,	G4	life-threatening,	G5	death;	Disease	response	according	to	RECIST	(Response	Evaluation	Criteria	in	Solid	Tumors)	ver.	1.1:	CR	complete	response:	disappearance	of	all	target	lesions,	PR	partial	response:	at	least	a	30%	decrease	in	the	sum	of	diameters	of	target	lesions,	 taking	as	reference	 the	baseline	sum	diameters,	MR/SD	minimal	response/stable	disease:	neither	sufficient	shrinkage	 to	qualify	 for	PR	nor	sufficient	 increase	 to	qualify	 for	PD,	PD	progressive	disease:	at	 least	20%	 increase	 in	 the	 sum	of	diameters	of	 target	 lesione,	 taking	as	 reference	 the	 smallest	 sum	on	study	 (this	 includes	 the	baseline	sum	if	that	is	the	smallest	on	study).	In	addition	to	the	relative	increase	of	20%,	the	sum	must	also	demonstrate	an	absolute	increase	of	at	least	5	mm.	(Note:	the	appearance	of	one	or	more	new	lesions	is	also	considered	progression)		 				
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